Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbyax in pediatric bipolar depression
NCT00844857Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2009
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial in bipolar disorder (BD) comparing Olanzapine/Fluoxetine Combination with Placebo (2 arms). Primary endpoint: Children's Depression Rating Scale Revised at 8 weeks. Started Apr 2009; status: completed.
02
Drugs
olanzapine + fluoxetine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00844857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00844857.